NRX Pharmaceuticals Profit Margin

NRX Pharmaceuticals (NRXP) currently reports a profit margin of -691.81% as of June 2026. That compares with -844850.0% in the prior-year period — up 99.9% year over year. That is below the Healthcare sector average of 19.13%. Use the charts on this page to explore NRX Pharmaceuticals's profit margin history and peer comparisons.

NRX Pharmaceuticals's profit margin increased from -844850.0% to -691.81% — a 99.9% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

NRX Pharmaceuticals's profit margin of -691.81% is lower than the Healthcare sector average of 19.13%. That is roughly 3716.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but NRX Pharmaceuticals's current -691.81% should be judged against Healthcare norms (sector average: 19.13%) and against NRXP's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -691.81%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 19.13%. From there, open related valuation or income-statement pages for NRX Pharmaceuticals, and consider following NRXP for alerts when major investors trade the stock.